PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend
The Pharmaceutical Benefits Advisory Committee has recommended that the drug triptorelin be made available on the PBS for unrestricted use. This change would provide essential treatment for breast cancer and endometriosis patients while also funding gender-affirming care for the first time.
Why it matters
This decision represents a significant shift in public health policy, potentially improving access to life-saving medication for diverse patient groups.
If taken up by the federal government, a triptorelin listing would mean gender-affirming care would be funded by the PBS for the first time. Illustration: Victoria Hart/Guardian design If taken up by the federal government, a triptorelin listing would mean gender-affirming care would be funded by the PBS for the first time. Illustration: Victoria Hart/Guardian design Health PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says
Get our breaking news email , free app or daily news podcast
Prefer the Guardian on Google The federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in